UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
MEDICAL DEVICES, DIAGNOSTICS & EQUIPMENT

Tower Cold Chain

Temperature-controlled logistics for pharmaceutical supply chains

Tower Cold Chain logo

Tower Cold Chain

Temperature-controlled logistics for pharmaceutical supply chains

Visit WebsiteContact Company

About Tower Cold Chain

Tower Cold Chain designs and supplies passive temperature-controlled shipping containers built specifically to protect pharmaceutical and life sciences cargo from spoilage and transit delays. Operating at the intersection of logistics innovation and cold-chain compliance, the company serves clients across global pharmaceutical supply chains who require reliable, validated thermal performance without active refrigeration systems.

The product portfolio spans a broad range of pallet and parcel shipper formats. Reusable pallet solutions include the CCT Tower Elite Universal series alongside the KTM and KT400 family, which covers standard US and Euro pallet configurations, double-stack options and ultra-cold variants. The KT400D Tower Flexi Fit Ultra Cold addresses the growing demand for controlled-temperature transport below standard refrigeration thresholds, including requirements typically associated with biologics and advanced therapies.

For parcel-level distribution, Tower Cold Chain offers reusable solutions under the KTEvolution range, available in 12, 26 and 57-litre configurations, alongside sustainable single-use lines including the CCT Rx Naturals, CCT EcoFlex and CCT TRUEtemp Naturals series in both seasonal and universal profiles. The KoolTemp GTS Evolution and single-use CCT Edge formats further extend coverage across ambient and cold-chain parcel requirements.

Thermal covers, including the Enshield PCM cover and Tyvek options, complement the container ranges and provide additional protection for temperature-sensitive shipments. The company also addresses onboard catering cold chain requirements, indicating reach beyond pharmaceutical logistics alone. Multilingual ordering and configuration tools are available directly via the company platform, supporting customers across European, North American, Korean, Chinese, Spanish, German and Portuguese markets.

Further information is available at towercoldchain.com.

Areas of Expertise

Cold Chain PackagingPassive Temperature ControlPharmaceutical Logistics

Services & Capabilities

Cold Chain PackagingPassive Temperature ControlPharmaceutical Logistics
Similar Companies

More in Medical Devices, Diagnostics & Equipment

A

Adaptix

Portable, low-dose 3D X-ray technology sits at the core of what Adaptix brings to medical, veterinary, and industrial imaging. Rather than tethering clinicians and engineers to fixed installations, the company's platform is built around a "3D first" philosophy, making volumetric imaging accessible at the point of care and in field environments where conventional CT infrastructure is impractical. In medical imaging, Adaptix focuses on reshaping diagnostic pathways. Its Ortho350 system targets orthopaedic applications, offering rapid access to 3D imaging in clinical practice without the footprint or cost burden of traditional CT. The company positions itself as a driver of point-of-care diagnostics, enabling professionals to capture the diagnostic quality they need outside of radiology departments. The veterinary offering extends the same approach into practice-based settings. The VetSA3D system addresses both standard companion animal imaging and exotics imaging, providing 3D diagnostic capability at a fraction of conventional CT cost, which is a meaningful advantage in specialist veterinary practice. Adaptix also operates a significant industrial imaging division under its NDT3D product line. Applications include non-destructive testing of composite structures, additive-manufactured metals, large battery assemblies, and electronic components. The move from 2D to 3D inspection is presented as delivering richer analytical insight, faster workflows, and greater confidence in quality decisions, particularly relevant to advanced manufacturing sectors. The breadth of markets served, spanning medical, dental, veterinary, and industrial inspection, reflects a platform technology strategy rather than a single-sector focus. Adaptix distributes internationally through a partner network. Further information is available at adaptix.com.

View profile
R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
A

Aerogen

With technology deployed in more than 80 countries and used to treat over 30 million patients, Aerogen has established itself as the global leader in acute care aerosol drug delivery. Founded in Galway, Ireland, the company built its reputation on a single, well-defined mission: ensuring that critically ill patients receive inhaled medication reliably, precisely, and without disrupting the ventilation or oxygenation they depend on.Vibrating Mesh Nebuliser PlatformThe company's core technology is the vibrating mesh nebuliser, a platform protected by more than 300 international patents and referenced in over 300 clinical publications. At the heart of the system is a mesh containing thousands of precision-formed apertures that act as a micropump, converting liquid medication into a fine, low-velocity aerosol optimised for deep lung deposition. The Aerogen Solo, the flagship single-patient-use device, is integrated into ventilator platforms from GE Healthcare, Draeger, Philips, Covidien, and virtually every major manufacturer of critical care ventilators, making it the de facto standard across intensive care units worldwide.One System Across the Respiratory JourneyA defining feature of the Aerogen portfolio is its continuity of care design. A single Aerogen Solo device supports patients across every stage of their hospital respiratory journey, from invasive mechanical ventilation in the ICU through non-invasive ventilation, high-flow nasal cannula therapy, and self-ventilating recovery, without the need to change hardware or recalibrate dosing. The Aerogen Ultra extends this flexibility by providing a handheld option for ambulatory or step-down settings. The continuous nebulisation tube set rounds out the range, enabling extended, precisely controlled drug administration where sustained dosing is clinically indicated.Aerogen operates internationally, with facilities in Galway, Ireland, and commercial presence across North America, Europe, and Asia-Pacific. The company supports a broad formulary of inhaled agents, including bronchodilators, corticosteroids, mucolytics, and antimicrobials, reflecting the breadth of pharmacological need in acute respiratory care.Further information is available at aerogen.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy